CJC-1295 (no dac) 5mg + Ipamorelin 5mg

CJC-1295 5 mg + Ipamorelin 5 mg is a high-purity dual-peptide research preparation supplied exclusively for scientific investigation and controlled laboratory experimentation. For research use only — not for human or veterinary use.  

Product Overview

CJC-1295 5 mg + Ipamorelin 5 mg is a dual-peptide research preparation developed for advanced laboratory investigations involving peptide receptor biology, molecular signalling and growth hormone-related regulatory pathways. The preparation combines two distinct research peptides within a single lyophilized vial. The CJC-1295 component was analytically characterised by Liquilabs as MOD GRF (1-29), while Ipamorelin was independently characterised as the second peptide component. This preparation contains 5 mg CJC-1295 together with 5 mg Ipamorelin. Independent analytical testing measured an assay content of 4.95 mg for the MOD GRF (1-29) component and 5.77 mg for the Ipamorelin component. Chromatographic analysis confirmed greater than 99.8 percent purity for both peptide components, while identity was independently evaluated through FTIR spectrum analysis, retention time confirmation and mass spectrometry. Microbiological testing reported 0 CFU/g for both total aerobic microbial count and total yeast and mold count, while bacterial endotoxin analysis returned a result of 0.006 EU/mg. Comprehensive elemental impurity screening additionally reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm. With both peptide components independently characterised, this dual-peptide preparation provides researchers with transparent batch-specific analytical documentation suitable for advanced peptide investigations and controlled in vitro laboratory studies.  

Peptide Overview

CJC-1295 and Ipamorelin are distinct peptide research compounds commonly investigated in experimental models involving peptide receptor signalling and molecular regulatory mechanisms. The CJC-1295 component in this preparation was analysed as MOD GRF (1-29), a modified growth hormone-releasing factor peptide used in controlled research involving peptide-mediated signalling pathways. Ipamorelin is a synthetic peptide investigated in laboratory models involving growth hormone secretagogue receptor-related signalling and molecular communication systems. Combining both compounds within a single research preparation allows investigators to study two different peptide signalling mechanisms under controlled experimental conditions. Because each peptide component has its own analytical characteristics, Liquilabs independently evaluated assay content, purity, FTIR spectrum identity and retention time identity for both components.  

Historical Background and Scientific Context

Advances in peptide engineering have enabled researchers to develop increasingly specialised compounds for investigating growth hormone-related signalling and receptor-mediated molecular communication. Growth hormone-releasing factor analogues and growth hormone secretagogue receptor-related peptides represent two distinct areas of peptide research, providing experimental models for investigating different signalling pathways within controlled laboratory environments. Modern analytical technologies including ultra-high-performance liquid chromatography, FTIR identification and mass spectrometry have significantly improved the ability to independently characterise individual components within combined peptide preparations. These techniques can be complemented by bacterial endotoxin testing, microbiological analysis and elemental impurity screening to provide comprehensive batch-specific analytical documentation. CJC-1295 5 mg + Ipamorelin 5 mg represents a dual-peptide research preparation designed for controlled scientific investigation of these molecular systems.  

Mechanistic Focus in Research

Within controlled laboratory environments, CJC-1295 and Ipamorelin may be investigated in relation to peptide receptor signalling and growth hormone-associated molecular pathways. Research investigations frequently explore:

• Peptide receptor signalling pathways
• Growth hormone-related molecular signalling
• Growth hormone-releasing factor research
• Growth hormone secretagogue receptor research
• Intracellular molecular communication
• Cellular regulatory mechanisms
• Comparative peptide investigations
• Combined peptide research models
• Controlled in vitro peptide studies

These experimental models allow researchers to investigate complex peptide-mediated signalling mechanisms while maintaining carefully controlled laboratory conditions.  

Analytical Verification (COA)

Each batch supplied by Grail Formula undergoes comprehensive independent third-party laboratory verification to confirm peptide identity, assay content, purity and microbiological quality. Analytical testing for this CJC-1295 5 mg + Ipamorelin 5 mg batch was performed by Liquilabs s.r.o. Czechia using chromatographic, spectrometric and microbiological analytical techniques. Batch: GF-CJCIPA5/5-B242

• CJC-1295 Content: 5 mg
• MOD GRF (1-29) Assay Content: 4.95 mg
• MOD GRF (1-29) Purity: greater than 99.8 %
• MOD GRF (1-29) Identification by FTIR Spectrum: 988
• MOD GRF (1-29) Identification by Retention Time: 0.999
• Ipamorelin Content: 5 mg
• Ipamorelin Assay Content: 5.77 mg
• Ipamorelin Purity: greater than 99.8 %
• Ipamorelin Identification by FTIR Spectrum: 975
• Ipamorelin Identification by Retention Time: 0.999
• Bacterial Endotoxins: 0.006 EU/mg
• Total Aerobic Microbial Count: 0 CFU/g
• Total Yeast and Mold Count: 0 CFU/g

Independent peptide screening measured an assay content of 4.95 mg for MOD GRF (1-29), with a reported analytical uncertainty of ±0.02 mg. Ipamorelin assay content was measured at 5.77 mg with a reported analytical uncertainty of ±0.03 mg. Purity analysis confirmed greater than 99.8 percent purity for both peptide components. FTIR spectrum analysis returned identity results of 988 for MOD GRF (1-29) and 975 for Ipamorelin, while retention time analysis returned 0.999 for both components. Mass spectrometry additionally provided molecular identity data for the tested preparation, including a reported molecular ion mass identification of 3367 Da for MOD GRF (1-29). Bacterial endotoxin testing returned a result of 0.006 EU/mg, remaining within the laboratory’s stated acceptable range of 0–0.5 EU/mg. Microbiological testing reported 0 CFU/g for total aerobic microbial count and 0 CFU/g for total yeast and mold count. Independent elemental impurity analysis reported arsenic, cadmium, mercury, lead, nickel, vanadium and cobalt below 0.001 ppm. These analytical procedures provide extensive independent batch-specific characterisation of both peptide components and important laboratory quality parameters.  

Research Applications

Within controlled laboratory environments, CJC-1295 5 mg + Ipamorelin 5 mg may be utilised in experimental models designed to investigate peptide receptor biology, molecular signalling and biochemical regulatory mechanisms. Examples of research applications include:

• Peptide receptor biology investigations
• Growth hormone-related signalling research
• Growth hormone-releasing factor investigations
• Secretagogue receptor-related research
• Intracellular signalling investigations
• Molecular pathway analysis
• Comparative peptide investigations
• Combined peptide research models
• Controlled in vitro peptide studies

These applications are intended exclusively for scientific and laboratory investigation.  

Grail Formula Quality

Every Grail Formula research compound is supported by comprehensive independent analytical verification and transparent batch-specific laboratory documentation. For this dual-peptide production batch, independent laboratory testing included:

• Individual assay determination for both peptide components
• Individual purity assessment
• FTIR spectrum identification
• Retention time verification
• Mass spectrometry identity analysis
• Endotoxin analysis
• Microbial contamination screening
• Elemental impurity screening
• Complete batch traceability

Independent laboratory testing helps provide researchers with reliable, reproducible and transparently documented research material suitable for advanced scientific investigation.  

When You Choose Grail Formula

When selecting Grail Formula, researchers receive independently verified research compounds supported by complete Certificates of Analysis and transparent batch-specific laboratory documentation. Our analytical verification programme includes individual assay determination, purity confirmation, FTIR spectrum identification, retention time verification, mass spectrometry identity analysis, endotoxin screening, microbiological analysis and comprehensive elemental impurity testing. Every production batch is accompanied by a downloadable Certificate of Analysis issued by Liquilabs s.r.o. Czechia, providing complete traceability and independent analytical verification of the tested research preparation.  

Research Use Limitation

• Used solely for laboratory and in vitro research
• Not approved for human consumption
• Not approved for veterinary use
• Not intended for diagnostic purposes
• Not intended for therapeutic applications
• Not permitted for clinical administration
• For research use only

• Independently analysed by Liquilabs s.r.o. Czechia
• Contains 5 mg CJC-1295 and 5 mg Ipamorelin
• Greater than 99.8 % purity confirmed for both peptide components
• MOD GRF (1-29) assay content verified at 4.95 mg
• Ipamorelin assay content verified at 5.77 mg
• Identification confirmed by FTIR spectrum and retention time analysis
• Mass spectrometry identity analysis performed
• Bacterial endotoxin level of 0.006 EU/mg
• No detectable heavy metals or microbial contamination
• Dual-peptide research compound
• For research use only – not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.